High endothelial venules (HEVs) in immunity, inflammation and cancer
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
High endothelial venules (HEVs) are specialized blood vessels mediating lymphocyte trafficking to lymph nodes (LNs) and other secondary lymphoid organs. By supporting high levels of lymphocyte extravasation from the blood, HEVs play an essential role in lymphocyte recirculation and immune surveillance for foreign invaders (bacterial and viral infections) and alterations in the body’s own cells (neoantigens in cancer). The HEV network expands during inflammation in immune-stimulated LNs and is profoundly remodeled in metastatic and tumor-draining LNs. HEV-like blood vessels expressing high levels of the HEV-specific sulfated MECA-79 antigens are induced in non-lymphoid tissues at sites of chronic inflammation in many human inflammatory and allergic diseases, including rheumatoid arthritis, Crohn’s disease, allergic rhinitis and asthma. Such vessels are believed to contribute to the amplification and maintenance of chronic inflammation. MECA-79+ tumor-associated HEVs (TA-HEVs) are frequently found in human tumors in CD3+ T cell-rich areas or CD20+ B-cell rich tertiary lymphoid structures (TLSs). TA-HEVs have been proposed to play important roles in lymphocyte entry into tumors, a process essential for successful antitumor immunity and lymphocyte-mediated cancer immunotherapy with immune checkpoint inhibitors, vaccines or adoptive T cell therapy. In this review, we highlight the phenotype and function of HEVs in homeostatic, inflamed and tumor-draining lymph nodes, and those of HEV-like blood vessels in chronic inflammatory diseases. Furthermore, we discuss the role and regulation of TA-HEVs in human cancer and mouse tumor models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“The tumor-draining lymph node (tdLN), which is the first regional lymph node draining established tumors, is considered as the major activation site of tumor-specific lymphocytes [128].”
BackgroundCancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Checkpoint blockade therapy with anti-PD-1 and antiCTLA-4 antibodies provides remarkable and durable responses for many patients across different types of cancer [317, 318, 320].”
BackgroundThe immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731 · cited 15×
“As specialized blood vessels for lymphocyte trafficking, TA-HEVs may be major gateways for entry of stem-like CD8+ T cells into tumors, and their therapeutic modulation could enhance the infiltration of these critical cells, thus increasing the efficacy of ICIs.”
BackgroundInfluentialTertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · cited 1×
“Indeed, it is important to identify biomarkers predicting response to ICIs because they are widely used for metastatic patients who are frequently non-responsive and develop severe immune-related adverse events [318, 339].”
BackgroundMiller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
B cells are associated with survival and immunotherapy response in sarcoma
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942 · cited 15×
“As specialized blood vessels for lymphocyte trafficking, TA-HEVs may be major gateways for entry of stem-like CD8+ T cells into tumors, and their therapeutic modulation could enhance the infiltration of these critical cells, thus increasing the efficacy of ICIs.”
BackgroundInfluentialTertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Clonal replacement of tumor-specific T cells following PD-1 blockade
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534 · cited 1×
“Interestingly, analyses of T cells in patients treated with ICIs revealed that continuous recruitment of fresh and less exhausted T cells from the periphery into the tumor may be important for clinical response [329, 330].”
BackgroundCCR7 and its ligands: balancing immunity and tolerance
Förster, R., Davalos-Misslitz, A. C., & Rot, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2297 · Cited by 1,410 · cited 5×
“Signaling through CCR7 induces conformational changes in the lymphocyte integrin LFA1, which mediate binding to ICAM1 and ICAM2 on the HEV endothelium, leading to firm arrest (sticking) of the lymphocytes.”
BackgroundInfluentialWnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031
Carriere, V., Roussel, L., Ortega, N., Lacorre, D.-A., Americh, L., Aguilar, L., Bouche, G., & Girard, J.-P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606854104 · Cited by 966 · cited 2×
“The gene encoding IL-33 was originally discovered as a gene highly expressed in MECA-79+ HECs isolated from human tonsils, and IL-33 was thus initially designated as “nuclear factor from high endothelial venules” (NF-HEV) [8, 9] 1 3 crossing the Golgi, these L-selectin ligands “en route” to the HEV lumen are present i…”
BackgroundSelf-citationCAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
How leukocytes cross the vascular endothelium
Vestweber, D. (2015) · Nature Reviews Immunology · doi:10.1038/nri3908 · Cited by 858 · cited 1×
“For additional information, readers are referred to “state-of-the-art” reviews on leukocyte transmigration [85, 86].”
BackgroundCombined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820 · cited 3×
“LTβR agonistic antibodies (anti-LTβR) were also reported to induce MECA-79+ TA-HEV and to enhance lymphocyte infiltration in distinct mouse tumor models, and treatment with anti-LTβR enabled response to anti-VEGFR2 and anti-PD-L1 combination therapy in a recalcitrant glioblastoma model [287].”
BackgroundPeripheral T cell expansion predicts tumour infiltration and clinical response
Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770
Malý, P., Thall, A. D., Petryniak, B., Rogers, C. E., Smith, P. L., Marks, R. M., Kelly, R. J., Gersten, K. M., Cheng, G., Saunders, T. L., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80137-3 · Cited by 714
HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes
Girard, J.-P., Moussion, C., & Förster, R. (2012) · Nature Reviews Immunology · doi:10.1038/nri3298 · Cited by 713 · cited 5×
“In homeostatic LNs, HEVs almost exclusively recruit naive and central memory lymphocytes [1].”
BackgroundMethodInfluentialSelf-citationHumby, F., Bombardieri, M., Manzo, A., Kelly, S., Blades, M. C., Kirkham, B., Spencer, J., & Pitzalis, C. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.0060001 · Cited by 537
The development of inducible bronchus-associated lymphoid tissue depends on IL-17
Rangel-Moreno, J., Carragher, D. M., de la Luz Garcia-Hernandez, M., Hwang, J. Y., Kusser, K., Hartson, L., Kolls, J. K., Khader, S. A., & Randall, T. D. (2011) · Nature Immunology · doi:10.1038/ni.2053 · Cited by 441
Fukuyama, S., Hiroi, T., Yokota, Y., Rennert, P. D., Yanagita, M., Kinoshita, N., Terawaki, S., Shikina, T., Yamamoto, M., Kurono, Y., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00339-4 · Cited by 207
Bao, X., Moseman, E. A., Saito, H., Petryanik, B., Thiriot, A., Hatakeyama, S., Ito, Y., Kawashima, H., Yamaguchi, Y., Lowe, J. B., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.018 · Cited by 167
Song, I. H., Heo, S.-H., Bang, W. S., Park, H. S., Park, I. A., Kim, Y.-A., Park, S. Y., Roh, J., Gong, G., & Lee, H. J. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.215 · Cited by 143
Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer
Koti, M., Xu, A. S., Ren, K. Y. M., Visram, K., Ren, R., Berman, D. M., & Siemens, D. R. (2017) · Bladder Cancer · doi:10.3233/blc-170120 · Cited by 78
Ohmichi, Y., Hirakawa, J., Imai, Y., Fukuda, M., & Kawashima, H. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101786 · Cited by 30
Regulation of fucosyltransferase-VII expression in peripheral lymph node high endothelial venules
(1998) · doi:10.1002/(sici)1521-4141(199810)28:10
Cited by
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
The roles of tertiary lymphoid structures in chronic diseases
Sato, Y., Silina, K., van den Broek, M., Hirahara, K., & Yanagita, M. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00706-z · Cited by 320
Tertiary lymphoid structures in anticancer immunity
Teillaud, J.-L., Houel, A., Panouillot, M., Riffard, C., & Dieu-Nosjean, M.-C. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 293
Asrir, A., Tardiveau, C., Coudert, J., Laffont, R., Blanchard, L., Bellard, E., Veerman, K., Bettini, S., Lafouresse, F., Vina, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.002 · Cited by 257
Self-citation
Metadata
- Authors
- Blanchard, L., & Girard, J.-P.
- Venue
- Angiogenesis
- Published
- 2021-05-06
- Volume
- 24
- Issue
- 4
- Pages
- 719-753
- ISSN
- 0969-6970 (ISSN-L)
- 1573-7209
- OpenAlex
- W3159563284
- Cited by
- 207
- References
- 36
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.